Acalabrutinib Nitroso Impurity 4
✓
100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
⬡
0 % Toleranz bei der Produktqualität

Lagerstandorte

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

Acalabrutinib Nitroso Impurity 4

● Auf Lager

Katalog-Nr.::VE0026047
CAS-Nr.::N/A
Summenformel::C10H9BrClN5O
Molare Masse::330.57 g/mol

Zusätzliche Informationen zu

Parent drug

Acalabrutinib

SMILES

O=NN(CCC1)[C@@H]1C2=NC(Br)=C3N2C=CN=C3Cl

InChI

InChI=1S/C10H9BrClN5O/c11-8-7-9(12)13-3-5-16(7)10(14-8)6-2-1-4-17(6)15-18/h3,5-6H,1-2,4H2/t6-/m0/s1

IUPAC-Name

(S)-1-bromo-8-chloro-3-(1-nitrosopyrrolidin-2-yl)imidazo[1,5-a]pyrazine

Beschreibung

Acalabrutinib Nitroso Impurity 4 is a process-related nitroso degradation product encountered during synthesis and stability of Acalabrutinib. This impurity exhibits distinct LC-MS and HPLC retention behavior and requires targeted analytical characterization including high resolution mass spectrometry, NMR confirmation, and validated chromatographic methods for accurate quantitation. Control strategy should address formation pathways, mitigation during API manufacture, acceptance criteria and forced degradation studies to define impurity limits. Availability of a certified reference standard supports method development and regulatory submissions. Detailed impurity profiling of Acalabrutinib Nitroso Impurity 4 is essential for risk assessment, specification setting and ensuring consistent API quality.

Angebot anfordern

„*“ zeigt erforderliche Felder an

Dieses Feld dient zur Validierung und sollte nicht verändert werden.
Products quotation
Name
Url